Senseonics (NYSE American:SENS) to Participate in Stifel 2025 Healthcare Conference

Germantown, MD — November 10, 2025 — Leads & Copy — Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company specializing in long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes, announced its participation in the Stifel 2025 Healthcare Conference in New York, NY. The conference will feature a fireside chat and one-on-one meetings. The fireside chat is scheduled for Wednesday, November 12, 2025, at 4:40 pm ET.

Interested parties can access a live and recorded webcast of the presentation in the “Investor Relations” section of Senseonics’ website.

Senseonics Holdings, Inc. is focused on creating glucose monitoring products. Its CGM systems, Eversense® 365 and Eversense® E3, feature a small sensor inserted under the skin and a smart transmitter worn over the sensor. Glucose data is sent every 5 minutes to a mobile app on the user’s smartphone.

Contact:
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com

Source: Senseonics Holdings, Inc.

×

Welcome!

BiotechReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy.

By Subscribing you will receive Daily Biotech Story Leads via email 10:30 am Mon-Fri.